GSE252944 AKT inhibition 10 v 5 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE252944_AKT inhibition_10_v_5_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE252944_AKT inhibition_10_v_5_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE252944_AKT inhibition_10_v_5_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE252944_AKT inhibition_10_v_5_human_up.

Results found

Linked to

 

Label

Description

 

Gene

non-coding RNA activated by DNA damage

Gene

general transcription factor IIi pseudogene 4

Gene

MIR34A host gene

Gene

transmembrane protein 198B (pseudogene)

Gene

HLA complex group 11

Gene

long intergenic non-protein coding RNA 1128

Gene

HOX transcript antisense RNA

Gene

zinc finger protein 37B, pseudogene

Gene

GOLGA2 pseudogene 5

Gene

STAG3 cohesin complex component like 5, pseudogene

  • Gene

    non-coding RNA activated by DNA damage


  • Gene

    general transcription factor IIi pseudogene 4



  • Gene

    transmembrane protein 198B (pseudogene)


  • Gene

    HLA complex group 11


  • Gene

    long intergenic non-protein coding RNA 1128


  • Gene

    HOX transcript antisense RNA


  • Gene

    zinc finger protein 37B, pseudogene


  • Gene

    GOLGA2 pseudogene 5


  • Gene

    STAG3 cohesin complex component like 5, pseudogene

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.